Lecture 15 and 16: Immunopharmacology Flashcards
(37 cards)
Rheumatoid arthritis
autoreactive T cell and antibodies against antigen localized to joint synovium
joint inflammation and destruction
Transplant rejection
difference in MHC between donor and recipient
results from unwanted immune response
Corticosteroids
decrease production of inflammatory cytokines
increase production of IL-10 in some cases
broadly immunosuppressive
dirty drug
extreme changes in transcriptional activity
prevent NF-kB nuclear translocation, no inflammatory cytokines
have anti-inflammatory cytokines
-omab
fully mouse
recognized as foreign in human
-ximab
chimeric
-zumab
humanized (not 100% human)
-umab
fully human
2 strategy to use mAbs to treat autoimmune disease
- destroy T-cells by binding an antibody that can be recognized by Nk cell Fc receptor
- block IL-2 receptor signalling, reduce T-cell activation
Muromonab-CD3
first monoclonal antibody (mouse IgG2 isotype) approved for use in humans
extremely potent immunosuppression
Binds to CD3 and cause clustering activation
T-cell activation initially
later cause internalization of muromonab CD3:CD3 complex
useful in organ transplant, can cause cytokine release syndrome
Basiliximab
human IgG1 isotype
antagonist of alpha subunit of IL-2 receptor
prevent maturation of T-cells
reduce antibody production from B-cell because reduce CD4 T-cells
Infliximab, adalimumab, golimumab
Anti-TNFa
binds to TNFa directly, not receptor
broadly immunosuppressive
Tumor infiltrating lymphocytes (TIL)
more = hot tumor, higher survival, better disease prognosis in anti-cancer therapies
less = cold tumor, less survival
Imiquimod
TLR7 (endosomal) agonist
cause NF-kB cytokine genes transcription
induce local inflammation
Traztuzumab
against HER2
highly expressed on breast cancer
recruit NK cell through Fc receptor (CD16) clustering
Antibody-drug conjugate deliver Mertansine (toxic payload) to cancer cell that express HER2
Rituximab
treats autoimmune disease
against cell surface protein CD20 (highly expressed on B-cell)
cause NK cell directed cancer cell lysis
2 Immune checkpoint receptors
CTLA-4 and PD-1
CTLA-4 inhibit CD40
PD-1 binds to PD-L1
Bispecific antibody
link T cell and tumor cell to enforce interactions
Etanercept
chimeric protein that binds to TNF-a and inactivates it
fusion to Fc greatly improves half-life
CAR-T cell therapy
engineered T-cell to bind to cancer biomarker to induce killing
can cause cytokine release syndrome (CRS)
give Tocilizumab to prevent binding of IL-6
decrease global inflammation allow patient to recover
Adjuvants
provided in vaccines to induce innate immune response (initiate antigen presentation)
mRNA vaccines
mRNA codes for antigen (spike protein)
stimulate immune response
mRNA acts as both adjuvant and antigen
3 steps to initiate innate immunity
- LPS (PAMPs) binds to TLR
- clustering of TLRs
- Activate NF-kB and rapid production of cytokines
TNFa and CXCL8 (IL-8)
released by macrophages
instruct neutrophils to extravasate and enter site of infection
Function of TNFa
induce ICAM-1 expression
increase vascular permeability